ArticleNeoplasia (New York, N.Y.)2013

Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Sumin Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.